Rolle der Gestagene

  • H. I. Wyss
Part of the Archives of Gynecology and Obstetrics book series (AGYO)


Exogene Estrogene bewirken eine 2–15fache Zunahme des Risikos, ein Endometrium-Carcinom zu entwickeln. Zahlreiche Studien belegen diesen Effekt, der bei allen Estrogenpräparaten eintritt, wenn eine Dosierung zur Behandlung der Menopausebeschwerden und zur Prophylaxe der Osteoporose gewährt wird (Tabelle 1).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albrecht BH, Schrift I, Tulchinsky D et al. (1981) Objective evidence that placebo and oral dedroxyprogesterone therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 139: 631PubMedGoogle Scholar
  2. 2.
    Andor J, Voegelin E, Wyss H, Schneider P, Tscherne K (1979) Medroxyprogesteronacetat in der Behandlung des Postmenopause-Syndroms. Presented at World Congress of Gynecology and Obstetrics IX, 25.–31. 10. 1979Google Scholar
  3. 3.
    Antunes CMF, Stollwy PD, Rosenshein MB et al. (1979) Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 300: 9PubMedCrossRefGoogle Scholar
  4. 4.
    Erlik Y, Meldrum DR, Lagasse LD et al. (1981) Effect of megestrol acetat on flushing and bone metabolism in postmenopausal women. Maturitas 3: 167PubMedCrossRefGoogle Scholar
  5. 5.
    Gambrell RD jr, Massey FW, Vastaneda TA (1980) Use of the progestin challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 55: 732PubMedGoogle Scholar
  6. 6.
    Gambrell RD jr (1980) Obstet Gynecol, pp 132–136Google Scholar
  7. 7.
    Gambrell RD jr (1984) Sex steroid hormones and cancer. Curr Probl Obstet Gynecol 14: 26Google Scholar
  8. 8.
    Gray LA jr, Christopherson WM, Hoover R (1977) Estrogens and endometrial cancer. Obstet Gynecol 49: 385PubMedGoogle Scholar
  9. 9.
    Henderson BE, Casagrande JT, Pike MC et al. (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Hoogerland DL, Buchler DA, Crowley JJ et al. (1978) Estrogen use-risk of endometrial carcinoma. Gynecol 6: 451Google Scholar
  11. 11.
    Horwitz RI, Feinstein AR (1978) Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 299: 1089PubMedCrossRefGoogle Scholar
  12. 12.
    Hulka BS, Kaufman DG, Fowler WC jr (1980) Predominance of early endometrial cancers after long-term estrogen use. JAMA 244: 2419PubMedCrossRefGoogle Scholar
  13. 13.
    Jelovsek FR, Hammond CB, Woodard BH et al. (1980) Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol 137: 85PubMedGoogle Scholar
  14. 14.
    Kelsey JL, LiVolsi VA, Holford TR et al. (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116: 333PubMedGoogle Scholar
  15. 15.
    King RJB, Whitehead MI, Campbell S et al. (1979) Effect of estrogen and progestin treatments on endometria from postmenopausal women. Cancer Res 39: 1094PubMedGoogle Scholar
  16. 16.
    King RJB, Dyer G, Collins WP et al. (1980) Intracellular estradiol, estrone and estrogen receptor levels in endometria from postmenopausal women receiving estrogens and progestins. J Steroid Biochem 13: 377–382PubMedCrossRefGoogle Scholar
  17. 17.
    Lane G, Siddle NC, Ryder TA et al. (1983) Dose-dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 287: 1241–1245CrossRefGoogle Scholar
  18. 18.
    Lane G, Siddle NC, Ryder TA et al. (1986) Effects of dydrogesterone on the oestrogenised postmenopausal endometrium. Br J Obstet Gynecol 93: 55–62CrossRefGoogle Scholar
  19. 19.
    Lane G, Siddle NC, Ryder TA et al. (1986) Is provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertil Steril 45: 345–352PubMedGoogle Scholar
  20. 20.
    LaVecchia C, Franceschi S (1982) Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 6: 1207Google Scholar
  21. 21.
    Lobo RA, McCormick W, Singer F et al. (1984) Depo-medroxyprogesterone for the treatment of postmenopausal women. Obstet Gynecol 63: 1PubMedGoogle Scholar
  22. 22.
    Lobo RA, Roy S, Shoupe D (1985) Estrogen and progestin effects on urinary calcium and calciotropic hormones in surgically-induced postmenopausal women. Horm Metabol Res 17: 370CrossRefGoogle Scholar
  23. 23.
    McDonald PC (1981) Estrogen plus progestin in postmenopausal women. N Engl J Med 305: 1644CrossRefGoogle Scholar
  24. 24.
    Mack TM, Pike MC, Henderson BE et al. (1976) Estrogens and endometrial cancer in a retirement community. N Engl J Med 294: 1262PubMedCrossRefGoogle Scholar
  25. 25.
    Mandel FP, Davidson BS, Erlik Y et al. (1982) Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 47: 511Google Scholar
  26. 26.
    Meldrum DR, Erlik Y, Davidson OJ et al. (1981) Effect of megestrol acetate (MA) on flushing and bone metabolism in postmenopausal women, abstract 87. 28th Annul Meeting of the Society of Gynecological Investigation, St. LouisGoogle Scholar
  27. 27.
    Morrison JC, Martin DC, Blair RA et al. (1980) The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 138: 99PubMedGoogle Scholar
  28. 28.
    Ottoson U-B, Carlstrom K, Damber J-E et al. (1984) Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parental administration. Br J Obstet Gynecol 91: 1111–1119CrossRefGoogle Scholar
  29. 29.
    Ottoson U-B, Carlstrom K, Damber J-E et al. (1984) Conversion of oral progesterone into deoxycorticosterone during postmenopausal replacement therapy. Acta Obstet Gynecol Scand 63: 577–579CrossRefGoogle Scholar
  30. 30.
    Paterson M (1982) A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynecol 89: 464CrossRefGoogle Scholar
  31. 31.
    Shapiro S, Kaufman DW, Slone D et al. (1980) Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 303: 485PubMedCrossRefGoogle Scholar
  32. 32.
    Smith DC, Prentice R, Thompson DJ et al. (1975) Association of exogenous estrogens and endometrial carcinoma. N Engl J Med 293: 1164PubMedCrossRefGoogle Scholar
  33. 33.
    Spengler RF, Clarke EA, Woolever CA et al. (1981) Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases. Am J Epidemiol 114: 497PubMedGoogle Scholar
  34. 34.
    Stavraky KM, Collins JA, Donner A et al. (1981) A comparison of estrogen use by women with endometrial cancer gynecologic disorders, and other illnesses. Am J Obstet Gynecol 141: 547PubMedGoogle Scholar
  35. 35.
    Studd JWW, Thorn MH, Paterson MEL et al. (1980) The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous oestrogens. In: Pasetto N, Paoletti R, Ambrus JL (eds) The menopause and postmenopause. MTP Press, Lancaster, pp 127–139CrossRefGoogle Scholar
  36. 36.
    Weiss NS, Szekely DR, English DR (1979) Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 242: 261PubMedCrossRefGoogle Scholar
  37. 37.
    Whitehead MI, King RJB, McQueen J et al. (1979) Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestin therapy. J R Soc Med 72: 322–327PubMedCentralPubMedGoogle Scholar
  38. 38.
    Whitehead MI, Townsend PT, Pryse-Davies J et al. (1981) Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305: 1599–1604PubMedCrossRefGoogle Scholar
  39. 39.
    Whitehead MI, Lane G, Dyer G et al. (1981) Oestradiol: the predominant intranuclear oestrogen in the endometrium of oestrogen-treated postmenopausal women. Br J Obstet Gynaecol 88: 914–918PubMedCrossRefGoogle Scholar
  40. 40.
    Whitehead MT, Townsend PT, Pryse-Davies J et al. (1982) Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 27: 539–548PubMedGoogle Scholar
  41. 41.
    Whitehead MI, Siddle N, Lane G, Padwick M, Ryder TA, Pryse-Davies J, King RJB, Mishell DR jr (1987) Menopause. Chicago, pp 317–334Google Scholar
  42. 42.
    Wigle DT, Grace M, Smith ESO (1978) Estrogen use and cancer of the uterine corpus in Alberta. Can Med Assoc J 118: 1276PubMedCentralPubMedGoogle Scholar
  43. 43.
    Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H. I. Wyss
    • 1
  1. 1.BaselSchweiz

Personalised recommendations